Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Published Date: 18 Feb 2023

Velmanase alfa-tycv: first FDA approval for non-CNS indications of alpha-mannosidosis

Read Full News

Latest News

Pediatricians Sidestep Trump CDC Vaccine Guidance

Growing distrust of the CDC has prompted pediatricians and health departments to seek independent vaccine guidance.

Antibody Drug Shows Promise in Refractory Lymphoma

Loncastuximab tesirine shows promise for patients with diffuse large B-cell lymphoma after multiple treatments, including relapse following chimeric antigen receptor T-cell therapy.

When Cost-Saving Software Undermines GP Prescribing

As part of the BMA's collective action, GPs are switching off prescribing prompts that critics say put cost ahead of patient care.

Acalabrutinib May Offer Durable Results in CLL Treatment

Acalabrutinib monotherapy offers sustained progression-free and overall survival in treatment-naive chronic lymphocytic leukemia.

Air Conditioning or Viruses: What’s Causing Summer Colds?

Air conditioning may affect indoor air quality and comfort, but clinicians should focus on viral transmission and heat-related illness when advising patients.

How Financial Toxicity Undermines Patient Trust

Patients hand over their lives in a single meeting. Dr Emil Lou discusses why financial strain is the single biggest threat to that fragile trust.

Todays Updates

Dupilumab Improves Allergic Fungal Rhinosinusitis Outcomes

Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Fecal Transplant Raises Peanut Tolerance

Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.

Dupilumab Shows Long-Term Benefits in CRSwNP

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.

Childhood Lupus: High Disease Activity Persists in Adulthood

Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.

First Dust Mite Immunotherapy Cleared for Scotland

Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.

Todays Updates

Dupilumab Improves Allergic Fungal Rhinosinusitis Outcomes

Dupilumab significantly improves sinus opacification and disease burden in patients with allergic fungal rhinosinusitis.

Fecal Transplant Raises Peanut Tolerance

Oral fecal microbiota transplant raises the amount of peanut that some highly allergic adults can tolerate, serving as proof of concept for microbiome-based food allergy therapy.

Dupilumab Shows Long-Term Benefits in CRSwNP

Dupilumab yields sustained benefits in terms of nasal congestion, sense of smell, and quality of life in patients with CRSwNP over 24 months in a real-world global registry.

Childhood Lupus: High Disease Activity Persists in Adulthood

Adults with childhood-onset systemic lupus erythematosus face a strikingly different disease trajectory than those diagnosed later in life, spending less time in the low disease activity state.

First Dust Mite Immunotherapy Cleared for Scotland

Acarizax is now the first house dust mite immunotherapy accepted by the SMC for patients with persistent allergic rhinitis.

Latest News

Growing distrust of the CDC has prompted pediatricians and health departments to seek independent vaccine guidance.

Loncastuximab tesirine shows promise for patients with diffuse large B-cell lymphoma after multiple treatments, including relapse following chimeric antigen receptor T-cell therapy.

As part of the BMA's collective action, GPs are switching off prescribing prompts that critics say put cost ahead of patient care.

Acalabrutinib monotherapy offers sustained progression-free and overall survival in treatment-naive chronic lymphocytic leukemia.

Air conditioning may affect indoor air quality and comfort, but clinicians should focus on viral transmission and heat-related illness when advising patients.

Patients hand over their lives in a single meeting. Dr Emil Lou discusses why financial strain is the single biggest threat to that fragile trust.

News All Time

Stem Cell Transplant Boosts Survival in Primary CNS Lymphoma

Among patients with primary CNS lymphoma who respond to induction therapy, high-dose chemotherapy with stem cell transplant improves survival compared with nonmyeloablative chemotherapy.

Stop ‘Nexting’ Patients and Start Mind Wandering Instead

Nexting is driven by schedule stress, but genuine mind wandering is a cognitive asset. Here’s how to tell the difference and stay present with patients.

FDA Neurology Roundup: July 2026

A monthly snapshot of FDA activity involving therapies for the prevention and treatment of neurologic diseases.

Does ERBB2-Low Predict Poor Survival in Gastric Cancer?

Baseline clinical characteristics, rather than ERBB2 status, appeared to explain the survival differences observed between patients with ERBB2-low and ERBB2-null advanced gastric cancer.

Otitis Media Consults, Antibiotic Rx Rebound Post-Pandemic

Childhood otitis media consultation rates and consultations with antibiotic prescribing, which fell sharply during the COVID pandemic, have recovered post-pandemic in the UK and Netherlands.

The Promise and Perils of Alternative Cancer Clinics

One family's experience reflects a growing issue in oncology: a hope that alternative therapies can succeed where conventional medicine has fallen short, a hope that can come with big risks.

NICE Criteria Miss 95% of Under-50s at Breast Cancer Risk

Full multifactorial assessment flagged 34.8% of women who developed breast cancer within a decade, against 4.4% under current NICE criteria.

Clearance of Hepatitis B Antigen Tied to Better Outcomes

Older age, low hepatitis B virus load, and loss of hepatitis B e antigen are linked to clearance of hepatitis B surface antigen, which predicts better long-term liver outcomes.

Who Owns Medical Knowledge Now?

Doctors are no longer the only source of medical knowledge in the room, and the future may depend on who preserves the most humanity.

Why Some Teens Are Vulnerable to Substance Use Disorders

Emerging research suggests vulnerability to substance use disorders may begin before the first drink or drug. Drs Leslie A. Hulvershorn and Paola P. Mattey Mora explain why.

FDA Psychiatry Roundup: July 2026

A monthly snapshot of FDA activity involving therapies used in the prevention, diagnosis, and treatment of psychiatric conditions.

The ‘Fourth Pillar of Cancer Care’ That’s Often Missed

Oncology has shown quitting tobacco improves outcomes. Now the field must learn how to incorporate cessation treatment alongside other cancer treatments.

Biosimilar Rituximab Matches Originator in ANCA Vasculitis

At 6 months, rituximab biosimilars show remission rates comparable to the originator in patients with granulomatosis with polyangiitis and microscopic polyangiitis, with no concerning safety signals.

Brain Health Lessons From Blue Zones

Kathrin LaFaver interviews fellow neurologist Aleksandra Pikula, who completed the Blue Zones certification from the American College of Lifestyle medicine on strategies for healthy brain aging.

MRI Models Predict Early HCC Recurrence After Resection

Two MRI-based models effectively predicted very early hepatocellular carcinoma recurrence among patients with single BCLC stage 0/A disease following curative resection.

Only 1 in 5 Second-Level Medicare Drug Appeals Succeed

Cancer drugs prescribed on-label but denied for coverage criteria are overturned most often on independent review, raising concerns about avoidable barriers to care.

Recommended News For You

For relapsed or resistant DLBCL, odronextamab produced positive results.

Cancer during young adulthood carries long-term mental toll, study finds

Breast cancer: A new target to eliminate dormant cells before they wake

Gene therapies for BCG-unresponsive bladder cancer have high response rates.

Millions of men could benefit from faster scan to diagnose prostate cancer

Nasal therapeutic HPV vaccine could prevent cervical cancer

A study on lung cancer provides additional proof of the value of screening.

Recommended Articles For You

Biomimetic Nanovesicles Target Senescent-Escape Cancer Stem Cells in Breast Cancer 

Neonatal Hematopoietic Transition and Blood Cell Maturation 

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients 

Blastic Plasmacytoid Dendritic Cell Neoplasm and the Dawn of AI-powered Diagnostics 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Diet and Prostate Cancer; TTFields OK'd for NSCLC; Cancer Studies Retracted

2.

PRO Data Strengthen Case for Dato-DXd in First-Line TNBC

3.

improvements in the treatment of prostate cancer resistant to chemotherapy.

4.

Tumor characteristics found to differ for melanomas in children, teens and young adults

5.

Canadian Group Calls for Earlier Colorectal Cancer Screening

1.

Pharmacological Frontier of Precision Oncology, Immunotherapies, and the Evolving Art of Treatment

2.

The Pros and Cons of Steroid Therapy for ITP

3.

The Risk Factors of Venous Thromboembolism and How to Lower Your Chances 

4.

Uncovering the Mystery of the Sessile Serrated Adenoma

5.

Understanding Sideroblastic Anemia and its Symptoms 

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

Asian Symposium on Advancement in Hematology and Oncology

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

International Cancer Conference

1.

An Eagles View - Evidence-based discussion on Iron Deficiency Anemia

2.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part I

3.

Managing ALK Rearranged Non-Small Cell Lung Cancer with Lorlatinib - Part III

4.

Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC

5.

A Continuation to The Evolving Landscape of First-Line Treatment for Urothelial Carcinoma

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot